APA

Kooijman M., van Meer P. J. K., Gispen-de Wied C. C., Moors E. H. M., Hekkert M. P. & Schellekens H. (20140610). The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. : Regulatory toxicology and pharmacology : RTP.

Chicago

Kooijman M, van Meer P J K, Gispen-de Wied C C, Moors E H M, Hekkert M P and Schellekens H. 20140610. The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. : Regulatory toxicology and pharmacology : RTP.

Harvard

Kooijman M., van Meer P. J. K., Gispen-de Wied C. C., Moors E. H. M., Hekkert M. P. and Schellekens H. (20140610). The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. : Regulatory toxicology and pharmacology : RTP.

MLA

Kooijman M, van Meer P J K, Gispen-de Wied C C, Moors E H M, Hekkert M P and Schellekens H. The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. : Regulatory toxicology and pharmacology : RTP. 20140610.